CliniVec™ Clinic-Ready Vector Consultation Service
VectorBuilder's CliniVec™ consultation service is guided by extensive real-world experience in CGT development and enables early-stage optimization of gene therapy vector design and production workflows, ensuring improved functionality and scalability. Our dedicated design team supports the smooth transition from research and validation to preclinical studies through careful consideration of key factors such as the efficacy, safety, and manufacturability of cell and gene therapy drug products. By aligning design and development choices with clinical efficacy and commercial feasibility in mind, we position drug products for successful development and accelerate their path to patients.
| Efficacy | Safety | Manufacturability | |
|---|---|---|---|
|
Vector Design Optimization
  
|
 |
|
|
|
Vector Backbone Optimization
|
|
|
|
|
Vector Component Compliance
|
|
|
|
|
Delivery System Optimization
|
|
|
|
|
Host Strain Optimization
E. coli
Virus Packaging Cells
|
|
|
|
|
Fermentation Optimization
|
|
||
|
Advanced QC
|
|
|
Why CliniVec™?
Conventional cell and gene therapy product development considers efficacy, safety, and manufacturability sequentially. This often results in R&D-stage drug candidates failing to meet safety requirements and GMP manufacturing standards, thereby requiring substantial redesign or optimization and leading to greater time and cost expenditures. In the CliniVec™ program, we work closely with developers to optimize their gene delivery vector design and production workflow early in the preclinical stage. Our team of experts leverage their extensive experience in intelligent therapeutic vector design to ensure maximum efficacy, safety, and manufacturability of vectors from the start.
By optimizing gene delivery vector design and production workflows early in the preclinical stage, the CliniVec™ approach strikes the right balance between the shortest path to clinic and long-term product success, ultimately saving time and costs.
Our CliniVec™ team provides personalized support to
help you navigate the intricacies of preclinical and clinical vector design.
Schedule a FREE CliniVec™ consultation now!Enhanced Efficacy Starts with Vector Design
Optimal vector design is key for therapeutic efficacy, and refining vector design is a multifaceted process that demands meticulous attention to various factors. Every part of the vector, from the backbone to individual vector components, should be thoughtfully designed and thoroughly validated for maximized functionality.
Vector backbone An effectively designed vector backbone is essential for developing therapeutics that are stable, potent, safe for patients, and feasible to manufacture commercially. For instance, the inverted terminal repeats (ITRs) of AAV transfer vectors play a critical role in AAV packaging and transgene expression, but these GC-rich regions are prone to mutations. Our analysis of over 300 AAV vectors collected from research and industry partners found that nearly 40% of ITRs contained previously undetected mutations (Nucleic Acids Res. 2025. doi: 10.1093/nar/gkaf697). To address this issue, MuteFree™ AAV was developed as a novel AAV transfer vector backbone with optimizations that vastly enhance stability, reducing mutation rate from about 40% to 0% (Figure 1).
Figure 1. The MuteFree™ AAV backbone achieves vastly enhanced ITR stability. (A) Integrity of AAV transfer plasmid ITRs were assayed by Sanger sequencing. (B) Conventional and MuteFree™ ssAAV and scAAV backbones were serially passaged 10 times in E. coli and ITR mutation rates measured. (C) Adoption of the MuteFree™ AAV backbone reduces ITR mutation rates from 48.1% to 0% for ssAAV and from 31.8% to 0% for scAAV.
Vector components In addition, the most effective vector components (e.g., promoters, enhancers, linkers, spacers, and polyA signals) should be established independently for each specific application. Coding sequence optimization, for instance, not only ensures the correct translation of the therapeutic gene but also facilitates its efficient expression and activity. In cell and gene therapy development, this involves strategic measures such as optimizing GC content and CpG islands as well as codon adaptation index, addressing challenges like cryptic splice sites and premature stop codons and polyA signals, and ensuring optimal mRNA/IDR tertiary structure reduction. Promoter engineering also plays a pivotal role in influencing gene expression, and careful manipulation of these regulatory regions can greatly enhance the efficacy of a vector (Figure 2). Besides the vector sequence itself, the arrangement of vector components is essential for enhanced function and minimized risk of unintended interactions.
Figure 2. Optimization of promoter sequence enhances overall therapeutic efficacy. Survival rates of transgenic knockout mice treated with gene replacement-encoded recombinant AAV9. This comparative analysis examines the efficacy of different sequence versions of the promoter driving GOI in the treatment of a genetic disorder. Treated control wild-type and non-treated control mutant mice were also observed.
Vector targeting Considerations for efficient drug delivery, such as selecting appropriate vector systems and optimizing envelope proteins or capsids to target specific tissues, are equally important for successful clinical outcomes. An effective approach to achieve this is through VectorBuilder’s end-to-end library screening services to engineer novel capsids with enhanced clinical efficacy, specificity, and manufacturability (Figure 3).
Figure 3. Novel capsid discovered through AAV capsid evolution drives robust and targeted expression. Comparison of transgene delivery (CMV>EGFP) to mouse cervical spine from a traditional nervous system-targeting AAV serotype and a novel AAV serotype discovered through AAV capsid evolution and screening.
Collectively, these efforts contribute to efficient clinical translation and improved therapeutic outcomes, reflecting the intricate nature of vector design optimization. As a result of designing hundreds of thousands of custom vectors for research every year, our experienced CliniVec™ design team is privy to the best methods for improving vector design and optimizing therapeutic development.
Preclinical Vector Design Must Include Safety Considerations
Ensuring the safety of cell and gene therapy vectors is paramount to their successful application in clinical settings. Developers must take into consideration a variety of areas including antibiotic resistance, regulatory elements with viral origin, toxicity and immunogenicity of vector components, and level of impurities such as hcDNA, residual proteins, and empty and partial capsids in manufacturing yield.
The presence of higher levels of impurities necessitates further purification steps and controls, leading to poor end yields and high cost of goods. From vector design with backbones optimized for high safety and manufacturability, including MiniVec™, to thorough validation of vector components, CliniVec™ ensures choices are made with the endpoint in mind. Vectors are designed to be suitable for clinical applications even during preclinical testing, ensuring they meet necessary safety standards at all scales and allowing for smooth transition from research and validation to GMP manufacturing.
Figure 4. Our MiniVec™ plasmid offers a safe alternative to regular plasmids. Our miniaturized plasmid backbone is as small as 500 bp, supports a novel combination of antibiotic-free and supplement-free selection, and can be applied across diverse viral and non-viral expression systems – resulting in enhanced flexibility and ease of production from development through GMP manufacturing.
Learn about our novel miniaturized plasmid with enhanced safety profile.
Explore MiniVec™ now!Design for Manufacturing from the Start
The manufacturability of gene therapy vectors involves balancing multiple factors to ensure scalability of upstream and downstream processes, reproducibility of yield and quality, and regulatory compliance. Selection and design of the vector backbone has a significant impact on both efficacy and manufacturability, and it is most effective when these are addressed together, because any changes after preclinical stage to optimize manufacturing may impact efficacy and require further validation studies. Additionally, further optimization of the host strain and fermentation conditions is essential for maximizing quantity and quality of vector production. Approaching therapeutic development with the end goal in mind and with the experience and expertise of the CliniVec™ team de-risks the treacherous road from discovery to therapy.
Figure 5. Yield optimization through host strain (A) and backbone (B) optimization. Vector constructs were cloned into different backbones and subjected to lab-scale fermentation to test for specific (bar) and volumetric (dot) yields.
Ready to streamline your cell and gene therapy development journey?
Experience the benefits of MiniVec™, MuteFree™ AAV, and CliniVec™ expertise.
Resources
Documents
Brochures & Flyers
